Known targets — ChEMBL curated mechanism
GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHMGCRMMP1MMP13MMP7MMP8PTGS1PTGS2ileSpolrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Butyric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 3/20 | 0.88 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.88 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.88 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.88 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.88 |
| ▸ | CA1 | P00915 | 3/20 | 0.57 |
| ▸ | CES2 | O00748 | 2/20 | 0.56 |
| ▸ | CES1 | P23141 | 2/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.45 |
| ▸ | FABP3 | P05413 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Butyric Acid SCHEMBL18039002 | 0.97 | FFAR3 (0.93) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Butyric Acid SCHEMBL123022 | 0.97 | FFAR3 (0.93) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Butyric Acid SCHEMBL1070956 | 0.94 | FFAR3 (0.88) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Butyric Acid SCHEMBL6837781 | 0.94 | FFAR3 (0.88) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Butyric Acid SCHEMBL7721221 | 0.94 | FFAR3 (0.88) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Butyric Acid SCHEMBL28795150 | 0.94 | FFAR3 (0.88) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Butyric Acid SCHEMBL8989559 | 0.94 | FFAR3 (0.88) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Butyric Acid SCHEMBL6234019 | 0.94 | FFAR3 (0.88) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Butyric Acid SCHEMBL17261591 | 0.94 | FFAR3 (0.94) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Butyric Acid SCHEMBL11419652 | 0.90 | FFAR3 (0.93) | FFAR3HDAC3HDAC1HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150080403-A1 | METHODS AND COMPOSITIONS FOR TREATING PARKINSON'S DISEASE | NEUROLIPID RESEARCH FOUNDATION, INC (US) | 2015-03-19 | — | — | US | disclosed |
| US-20100022444-A1 | COMBINATION THERAPY FOR MODULATION OF ACTIVITY AND DEVELOPMENT OF CELLS AND TISSUES | BODYBIO, INC. (US) | 2010-01-28 | — | — | US | disclosed |
| US-20080254017-A1 | Methods and compositions for treating symptomes of diseases related to imbalance of essential fatty acids | BODYBIO, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| US-20070004639-A1 | Methods and compositions for treating Parkinson's disease | BODYBIO, INC. (US) | 2007-01-04 | — | — | US | disclosed |